header image
GfK Healthcare July 2010  
 
 
 
Regulatory Update: State Reporting Requirements at a Glance
 

 
 
 

By Dan Fitzgerald, Chief Financial Officer

Working with information provided by industry groups such as CASRO, PMRG, PBIRG and MRA, and through careful monitoring within our own physician community, GfK Healthcare continuously tracks state laws and statutes that govern the compensation of physicians and reporting requirements by pharmaceutical companies or their marketing research agencies in an effort to prevent violation of any state laws. 

Recently, a statute in Minnesota was updated to allow payments to physicians who participate in bona fide pharma survey research in that state and eliminated reporting requirements for market research payments.

 
   
Read More
 
 
 
 
What Lies Ahead: Thoughts From Health Care Marketing Research CEOs
 

 
 
 

GfK Healthcare Chief Executive Officer Richard B. Vanderveer, Ph.D., participated in CEO panels at both PMRG and PBIRG’s spring conferences. This month’s published document for The Orange Pages offers a glimpse of what he and other health care marketing agency leaders see as the future of the profession for both pharmaceutical company and agency researchers.

With the interface between pharmaceutical company marketing researchers and their agency counterparts in a major state of flux, it is not surprising that one word could be used to describe the theme of both sessions: change.

 
   
Read More
 
 
 
 
Did You Miss the June Issue of Pipeline?
 

 
 
 

Click here to read the issue, which includes:

  • What is Design and How Will It Help Us to Rethink Health Care?
  • Turning Customer Ambivalence Into Loyalty
  • Vanderveer's Views: Marketing Research Budget Cycles – A Growing Headache for Us All 

Pipeline archive is available. Skim the directory and select articles you missed. Access subscriber opt-in/comment form.

 
 
 
 
 
   
 
 

What Is Really Happening Out in the Marketplace?

When it comes to data on which major decisions are made, the pharmaceutical industry can be a funny place indeed. In many ways, we are consistent with the saying that “Things that are important are usually difficult to measure, while things that are easy to measure are usually not important.” Nonetheless, a growing number of databases has populated the landscape, and decision makers insist on getting their numbers as quickly as possible. 

More specifically, many of the most important budget decisions made in the pharmaceutical industry pertain to the size and allocation of promotional spends aimed at physicians. Moreover, many of these decisions are based on audits and/or self reports from pharmaceutical sales representatives (PSRs) about the number, length and nature of their interactions with physicians. That having been said, a moral hazard clearly exists here, with PSRs wanting to appear as busy, productive and impactful as possible.

Additionally, many of the sales managers in the home office are former PSRs themselves, and thus are biased toward viewing what is happening in the field today as paralleling what they were able to do 20 years ago. They also have the moral hazard of wanting to believe that their carefully selected, carefully trained and well-compensated sales force is effectively representing their products. Megabucks are spent in this promotional channel every year... 

 
   
Read More
 
 
 
 
Contact   |  GfK Healthcare
 
  Copyright © 2010 GfK Healthcare  
 
  Published by GfK Healthcare, 587 Skippack Pike, Blue Bell PA 19422.
Reproduction or any other form of duplication only with the written permission of the publisher. All rights reserved.